Indication
in combination with carboplatin–paclitaxel (CP) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).
Medicine details
- Medicine name:
- retifanlimab (Zynyz)
- SMC ID:
- SMC2977
- Pharmaceutical company
- Incyte Biosciences UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC